Literature DB >> 18384959

Long-term trials of pregabalin and duloxetine for fibromyalgia symptoms: how study designs can affect placebo factors.

Roland Staud1, Donald D Price.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18384959      PMCID： PMC2453778          DOI： 10.1016/j.pain.2008.03.005

Source DB:  PubMed          Journal:  Pain        ISSN： 0304-3959            Impact factor:   6.961


× No keyword cloud information.
  6 in total

Review 1.  Pregabalin: a review of its use in fibromyalgia.

Authors:  Katherine A Lyseng-Williamson; M Asif A Siddiqui
Journal:  Drugs       Date:  2008       Impact factor: 9.546

Review 2.  A comparison between enriched and nonenriched enrollment randomized withdrawal trials of opioids for chronic noncancer pain.

Authors:  Andrea Furlan; Luis E Chaparro; Emma Irvin; Angela Mailis-Gagnon
Journal:  Pain Res Manag       Date:  2011 Sep-Oct       Impact factor: 3.037

Review 3.  The placebo response: relationship to outcomes in trials of postherpetic neuralgia.

Authors:  Gordon Irving
Journal:  Clin Drug Investig       Date:  2010       Impact factor: 2.859

4.  Role of Placebo Factors in Clinical Trials with Special Focus on Enrichment Designs.

Authors:  Roland Staud; Donald D Price
Journal:  Pain       Date:  2008-09-11       Impact factor: 6.961

5.  Importance of Measuring Placebo Factors in Complex Clinical Trials.

Authors:  Roland Staud; Donald D Price
Journal:  Pain       Date:  2008-08-05       Impact factor: 6.961

6.  New treatment options in the management of fibromyalgia: role of pregabalin.

Authors:  Grazyna Zareba
Journal:  Neuropsychiatr Dis Treat       Date:  2008-12       Impact factor: 2.570
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.